Back to top

Analyst Blog

XOMA Corporation (XOMA - Snapshot Report) recently announced encouraging data from a phase III study PATH (Perindopril Amlodipine for the Treatment of Hypertension: n=837), which evaluated the fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate in patients suffering from hypertension.

The phase III PATH trial, initiated in February 2012, compared the efficacy and safely of FDC perindopril/amlodipine with perindopril or amlodipine alone. Data from the study revealed a statistically significant reduction in both sitting diastolic and sitting systolic blood pressure in patients in the FDC arm compared to those treated with perindopril and amlodipine alone.

The encouraging data from the phase III PATH trial is expected to support the submission of the new drug application (NDA) to the US Food and Drug Administration (FDA). FDC perindopril/amlodipine is already marketed in 91 ex-US countries by partner Laboratoires Servier, a privately-owned French pharmaceutical company, under the trade name Coveram.

Notably, in January 2011, XOMA inked a deal with Les Laboratoires Servier to acquire the US rights to the perindopril franchise from the latter. The perindopril franchise includes Aceon (perindopril erbumine), an angiotensin converting enzyme (ACE) inhibitor and three other fixed dose combination candidates, including FDC perindopril/amlodipine.

Aceon is approved for treating patients suffering from essential hypertension. The drug is also marketed for reducing the risk of cardiovascular death or nonfatal myocardial infarction in patients with stable coronary artery disease.

XOMA has collaboration agreements with other companies like Novartis AG (NVS - Analyst Report) and Takeda Pharmaceuticals (TKPYY).

Our Recommendation

Currently, we have a Neutral long-term recommendation on XOMA. The company carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%